Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07822529 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Long Term Persistency of Guselkumab in Adult Participants With Inflammatory Bowel Disease

Study acronym: GO-ON
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Sep 18, 2026 to Sep 14, 2026 · Study sites: 0 to 1 · Completion date: Apr 19, 2030 to Apr 15, 2030 Show 3 more changesShow less
    • Start date changed from estimate of Sep 18, 2026 to Sep 14, 2026
    • Study sites: 0 to 1
    • Completion date: Apr 19, 2030 to Apr 15, 2030
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to evaluate treatment persistence of guselkumab (that is how long a person keeps taking their prescribed medicine or continues with their treatment plan without stopping) in participants with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are inflammatory bowel diseases, a group of inflammatory conditions of the colon and small intestine.
Trial Details
NCT Number NCT07822529
Lead Sponsor Janssen Research & Development, LLC
Conditions Inflammatory Bowel Diseases
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov